0645 GMT - Jardine Matheson's execution of its strategic priorities outlined during its June investor day remains on track, says DBS Group Research's Elizabelle Pang in a note. The Hong Kong-based conglomerate is likely to continue making further progress on capital recycling in 2H ahead of its I-MED acquisition's expected completion, she says. Jardine's capital recycling and portfolio simplification could be among rerating catalysts for the stock. DBS retains a buy rating and $90.00 target price. The Singapore-listed shares are down 1.0% at $66.91.